Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

174.66USD
23 Apr 2018
Change (% chg)

$3.10 (+1.81%)
Prev Close
$171.56
Open
$171.62
Day's High
$176.97
Day's Low
$171.26
Volume
1,477,955
Avg. Vol
1,622,213
52-wk High
$201.23
52-wk Low
$152.16

Select another date:
Photo

Express Scripts targets new migraine drugs to change U.S. pricing dynamic

LOS ANGELES The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it.

FOCUS-Express Scripts targets new migraine drugs to change U.S. pricing dynamic

LOS ANGELES, April 24 The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it.

Amgen's Aimovig halved migraine days in 30 percent of trial patients

LOS ANGELES A late-stage trial of Amgen Inc's experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.

Amgen's Aimovig halved migraine days in 30 pct of trial patients

LOS ANGELES, April 17 A late-stage trial of Amgen Inc's experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.

BRIEF-Amgen Says CEO Robert Bradway's FY 2017 Total Compensation Was $16.9 Mln

* AMGEN INC SAYS CEO ROBERT BRADWAY'S FY 2017 TOTAL COMPENSATION WAS $16.9 MLN VS $16.9 MLN IN FY 2016 - SEC FILING Source text: [https://bit.ly/2EDxA7i] Further company coverage:

BRIEF-Amgen Plans To Build A New Biomanufacturing Plant in Rhode Island

* AMGEN ANNOUNCES RHODE ISLAND WILL BE LOCATION OF FIRST US NEXT-GENERATION BIOMANUFACTURING PLANT

Rhode Island governor says Amgen will build another plant in state

Amgen Inc will build a $165 million next-generation biopharmaceutical plant adjacent to its West Greenwich, Rhode Island manufacturing campus, the state governor's office told Reuters on Tuesday.

Rhode Island governor says Amgen will build another plant in state

April 10 Amgen Inc will build a $165 million next-generation biopharmaceutical plant adjacent to its existing West Greenwich, Rhode Island manufacturing campus, the state governor's office told Reuters on Tuesday.

BRIEF-‍European Commission Approves Expanded Indication For Amgen's Xgeva

* ‍EUROPEAN COMMISSION APPROVES EXPANDED INDICATION FOR AMGEN'S XGEVA (DENOSUMAB) FOR PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA​ Source text for Eikon: Further company coverage:

FDA expands use of Amgen leukemia drug Blincyto to patients with relapse risk

The U.S. Food and Drug Administration on Thursday expanded the use of Amgen Inc's leukemia drug Blincyto to include patients who are in remission but still have residual signs of the disease.

Select another date: